Specific PDE5 inhibitors are currently under clinical trial during prenatal life for the treatment of fetal growth restriction (FGR), neonatal pulmonary hypertension or preeclampsia46–48 to target vascular smooth muscle layers, thus the safety of these molecules on the development of the aortic wall needs to be warranted. Here, PDE5A is linked to fetal growth restriction.